Arkansas Cannabis: $8.10/g Flower, 24% Legal Capture, and 110,000 Patients Doing the Work of a Legal Market

Arkansas has run a medical cannabis program since 2019 and generated $291 million in sales in 2025 — a new state record. The math behind that number is unusual: approximately 110,000 active patient cardholders, each spending roughly $210/month, are carrying the entire regulated market. The other three-quarters of Arkansas's estimated cannabis consumer base has no legal pathway to purchase at all. This isn't a price failure or a density failure. It's a structural access failure enforced by a hard dispensary cap, a governor who vetoed cannabis access expansion in April 2025, and a state where adult-use legalization has been blocked at every turn. The 24% capture rate isn't an underperforming market — it's a capped one.

Market Overview

Arkansas voters approved the Arkansas Medical Marijuana Amendment in November 2016 (53–47%), and the first dispensary opened in May 2019. The program is regulated by the Arkansas Medical Marijuana Commission under the Department of Finance and Administration (DFA), with patient registry administered by the Arkansas Department of Health.

Key metrics:

• 36 active dispensaries (37 licensed; state cap of 40; two licenses unawarded)
• $291.1M in 2025 sales — a new annual record (DFA)
• $8.10/g implied flower price (derived from 79,223 lbs sold ÷ $291.1M revenue)
• ~10.5% combined tax (6.5% state sales tax + 4% privilege tax)
• ~$9.00/g estimated final consumer price
• ~24% estimated legal capture (dollars)
• ~$1.6 billion cumulative sales since 2019 launch
• Medical-only — adult-use failed at the ballot in 2022; a 2024 expansion initiative was blocked by the Arkansas Supreme Court before votes could be counted
• 18 qualifying conditions plus a catch-all approved by the Arkansas Department of Health

Flower Pricing

Arkansas's $8.10/g figure is derived directly from state-reported data: 79,223 pounds sold in 2025 converts to approximately 35.9 million grams, against $291.1 million in revenue. It is not a menu-scraped estimate. At $8.10/g pre-tax, Arkansas sits in the upper tier of legal medical markets nationally — reflecting the absence of adult-use competition, a hard dispensary cap, and a small cultivation base of eight licensed facilities.

At $8.10/g, Arkansas is pricing above every adult-use market in the dataset and above Pennsylvania's medical-only market — but well below Hawaii and Vermont. The ~10.5% combined tax is relatively modest, so the price floor is driven by supply-side constraints: eight cultivators, 36 dispensaries, and no interstate competition.

Tax Structure

• 6.5% state sales tax on each patient purchase at dispensary
• 4% privilege tax on cultivator-to-dispensary sales
• Combined effective burden: ~10.5% at consumer level
• Medical cannabis is subject to standard sales tax — no exemption
• Tax revenue in 2025: $32.3 million
• Cumulative tax revenue since 2019: $218+ million
• Revenue directed to: University of Arkansas for Medical Sciences National Cancer Designation Trust Fund; food insecurity programs (by legislative discretion)

At 10.5%, Arkansas's medical cannabis tax burden is moderate — lower than most adult-use states and lower than Vermont's 20%. The privilege tax structure adds an unusual layer: cultivators pay 4% on wholesale transfers before the product even reaches patients. That embedded cost compounds with the retail sales tax at the consumer level.

Total Addressable Market

Arkansas's adult population 21+ is approximately 2.28 million. Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:

• 2,280,000 adults 21+
• 410,400 estimated regular consumers (18%)
• TAM at $8.10/g: ~$1.21B annually

Against $291.1M in 2025 actual sales:

Arkansas's estimated legal market capture rate: 24%.

The interpretation here differs fundamentally from adult-use markets. In a state like Illinois (30% capture), the gap reflects price and tax failures — consumers who could buy legally choose not to because the regulated product is too expensive. In Arkansas, the gap is structural access. Approximately 110,000 Arkansans hold active patient cards. Against an estimated consumer base of 410,400, that's roughly one in four estimated consumers with any legal purchase pathway at all. The remaining three-quarters have no option but informal channels.

The patient spending data confirms the program is working well for those inside it. $291.1M divided by 110,000 active cardholders equals approximately $210/month per active patient — nearly identical to Vermont's $197/month per consumer in a fully open adult-use market. The patients who have legal access are using it heavily and consistently. The program isn't underperforming. It's capped.

Revenue Trend

The 2024 dip followed by a 2025 record is notable. Sales fell despite patient card counts continuing to grow — suggesting per-patient spend compressed in 2024 before rebounding. The 2025 record was driven by both volume (79,223 lbs vs 75,598 in 2024, +4.8%) and price holding at $8.10/g.

Average monthly sales in 2025: ~$24.3M/month, with December the strongest month at $25.7M.

Dispensary Density

Arkansas operates 36 active dispensaries for a state of 3.07 million people — a density of approximately 1.6 dispensaries per 100,000 adults 21+. That is among the lowest retail densities in any legal cannabis market in this dataset. In practice, legal access is further constrained to the 110,000 patients who hold cards — making the effective density question moot. The stores that exist are not the binding constraint. The card requirement is.

Revenue per dispensary: $291.1M ÷ 36 = $8.09M/store annually — comparable to Maryland's medical-era figures and well above most adult-use states on a per-store basis, reflecting the captive patient customer base and near-zero price competition.

The state cap of 40 dispensaries — with two licenses still unawarded — is a binding structural ceiling. Governor Sarah Huckabee Sanders vetoed HB 1889 on April 16, 2025, a bill that would have permitted drive-through pickup, revised delivery rules, and dispensary tours, stating it "would expand access to usable marijuana." DFA Secretary Jim Hudson has said he is "in no hurry" to award the final two licenses. The state's political posture is explicitly oriented toward containing rather than expanding the program.

Home Cultivation

Home cultivation is not permitted under the Arkansas Medical Marijuana Amendment. Patients must purchase exclusively through licensed dispensaries. This is worth noting but not analytically significant — as the home cultivation economics show, growing your own rarely saves money once equipment, time, and input costs are accounted for. The absence of a home grow option in Arkansas doesn't meaningfully change the market picture.

What the CHS Literature Missed

The University of Arkansas for Medical Sciences — the institution that receives cannabis tax revenue through the UAMS National Cancer Designation Trust Fund (with Act 123 of 2025 also routing a portion to the Food Insecurity Fund for school breakfast programs) — produced a patient education brochure on medical marijuana in 2022, developed with SAMHSA funding and distributed through Arkansas DHS. On the subject of CHS, the document states:

"Marijuana use can cause cannabinoid hyperemesis syndrome (CHS). This causes severe vomiting. This is rare and normally only happens with long-term use of marijuana every day."

That's the Arkansas state health apparatus's own characterization: rare, and limited to daily long-term users. The brochure was authored by researchers at UAMS — the same institution positioned as the primary beneficiary of cannabis tax revenue — and distributed through the state's official prevention infrastructure at ARPrevention.org.

Arkansas has run a patient-registry medical program since 2019 with 110,000 named, tracked cardholders. If CHS affected 17–33% of daily users as some clinical estimates claim, approximately 19,000–36,000 Arkansas patients would be active sufferers within a program that knows who they are, what conditions they're treating, and which physicians certified them. The state's own medical infrastructure — including UAMS, which treats patients at Arkansas's largest academic medical center — describes the condition as rare. Seven years of ADH annual program reports contain no CHS incidence data, no CHS hospitalizations attributed to the medical program, and no CHS public health advisories.

The discrepancy between published clinical prevalence estimates and what Arkansas's own state and university health systems observe and report is consistent with what population-level consumption analysis shows about actual CHS frequency. Arkansas's medical registry makes the test unusually clean: the patients are identified, the program is monitored, and the institution receiving the tax revenue has characterized the condition as rare in its own educational materials.

The Bottom Line

Arkansas's cannabis market is doing exactly what a capped medical program does: generating strong revenue from a small, committed patient base while leaving the majority of estimated consumers outside the legal system entirely. The 24% capture rate isn't a policy failure — it's arithmetic. One in four estimated consumers has a card; roughly one in four dollars flows through the regulated market.

The constraint isn't price (10.5% tax is moderate), density (36 stores is workable for a medical program), or patient spending behavior ($210/month per cardholder is strong). The constraint is intentional. A governor who vetoes access expansion, a secretary in no hurry to issue the final two licenses, and a constitutional amendment written to limit rather than expand the program — Arkansas's cannabis policy is functioning as designed by those who currently control it.

Adult-use legalization failed at the ballot in 2022. A separate 2024 medical-marijuana expansion initiative was blocked by the Arkansas Supreme Court before votes could be counted. As of May 2026, no cannabis measure is certified for the Arkansas ballot. Until that changes, the estimated 300,000 Arkansas cannabis consumers without medical cards will remain in the informal market, and the state's 24% capture rate will remain a feature of the program rather than a problem to solve.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.